Anthem Biosciences Ltd: Is This the Biotech Banger India’s Been Humming For?
1. At a Glance
Anthem Biosciences, a biotech CRDMO juggernaut, is storming into the market with a ₹3,395 Cr IPO. A 100% Offer For Sale, no fresh cash for R&D splurges. But this Bengaluru-based enzyme-and-patent powerhouse has the metrics, margins, and mindshare to make you look twice.
2. Introduction with Hook
Imagine if you could rent a scientific brain lab that makes your drug idea real, scales it, tests it, and ships it globally—without lifting a pipette. That’s Anthem Biosciences. – Market Cap: ₹31,867 Cr (post-IPO) – PAT Margin: A juicy 23.38% – ROCE: A pharma-fantasy 26.88%
While the rest of us were Googling “What’s a CRDMO?”, Anthem was adding 196 drug discovery projects and locking in 550+ customers across 44 countries. No jokes—this is a nerd empire.
3. Business Model (WTF Do They Even Do?)
Anthem is a Contract Research, Development, and Manufacturing Organization (CRDMO). It helps drug companies with:
Drug discovery (R&D from scratch)
Process development (making drugs better/cheaper)
Commercial manufacturing (mass production)
They’re into both small molecules and biologics, fermentation-based APIs (probiotics, enzymes, peptides), and even work on biosimilars. Key services:
Fermentation platforms
Biotransformation
Analytical development
Regulatory support
This isn’t just lab coats and pipettes. It’s full-stack biopharma for hire.
